Angiotensin-converting enzyme 2

Avirmax Inc. Announces Issuance of U.S. Patent Covering Catalysis Deactivated Angiotensin-Converting Enzyme 2 (ACE2) Variants for Treatment of Beta Group SARS-COV Viral Infection

Retrieved on: 
Saturday, October 8, 2022
Method, Immunoglobulin G, SARS-COV-2, Severe acute respiratory syndrome coronavirus 2, Therapy, Infection, Rita Raave, Patient, Catalysis, Human coronavirus NL63, Epithelium, GOI, San Francisco Bay Area, AAV, ACE2, United States Patent and Trademark Office, Patent, ECD, Angiotensin-converting enzyme 2, USPTO, SARS, COVID-19, Vaccine

11,453,869, which is directed to the composition and methods related to the use and administration of catalysis deactivated angiotensin-converting enzyme 2 (ACE2) for preventing SARS-COV-1 and SARS-COV-2 infection.

Key Points: 
  • 11,453,869, which is directed to the composition and methods related to the use and administration of catalysis deactivated angiotensin-converting enzyme 2 (ACE2) for preventing SARS-COV-1 and SARS-COV-2 infection.
  • Human ACE2 has been confirmed as a specific receptor for several group coronaviruses including severe respiratory syndrome (SARS) coronavirus (SARS-CoV-1), a low pathogenic coronavirus of HCoV-NL63, a member in -coronavirus group and SARS-CoV-2, the causative agent of COVID-19.
  • The rAAV mediated expression of the catalysis deactivated ACE2 in nasal/olfactory epithelium therefore acts as a decoy receptor for SARS-COV blocking infection of epithelial cells and the following viral replication.
  • Our ultimate goal is to deliver patients with effective, safe, long-acting AAV-mediated biotherapeutics in the most affordable and accessible manner possible.

Bio-Thera Solutions Announces Enrollment Completed in Phase 1 Study for BAT2022, a Broadly Potent Neutralizing Bi-specific Antibody Against SARS-CoV-2

Retrieved on: 
Tuesday, September 27, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Autoimmunity, Therapy, Degenerative disease, Safety, Trial of the century, Engineering, COVID-19, IC50, ADC, Risk, Angiotensin-converting enzyme 2, Research, Severe acute respiratory syndrome coronavirus 2, IND, Antibody, Intellectual property, News, Plasma, Mouse, Forward-looking statement, Infection, Patient, Cancer, IDEAL, Epitope, WeChat, Vaccine, ACE2, DLT, Immunodeficiency, Pharmacy, RBD, Human, Marketing, Intelligence, Pharmaceutical industry, Virology, Omicron

BAT2022 is a broadly potent neutralizing bi-specific antibody against SARS-CoV-2.

Key Points: 
  • BAT2022 is a broadly potent neutralizing bi-specific antibody against SARS-CoV-2.
  • Therefore, novel antibodies that maintain their neutralization strength and breadth against the abovementioned resistant variants and possibly future emerging variants are urgently needed.
  • By utilizing its proprietary IDEAL (Intelligent Design and Engineered Antibody Libraries) platform, the Bio-Thera team has discovered and developed BAT2022, a broadly potent neutralizing bi-specific antibody against SARS-CoV-2.
  • This news release contains certain forward-looking statements relating to BAT2022 or the product pipelines in general of Bio-Thera Solutions.

Penn Dental Medicine Study Shows Gum with Plant Protein May Reduce SARS-CoV-2 Transmission

Retrieved on: 
Tuesday, April 12, 2022
Chewing gum, Fraunhofer Society, Clinical trial, Hypertension, Perelman School of Medicine at the University of Pennsylvania, Plant, COVID-19, Research, Wistar Institute, Exocrine gland, RNA, Patient, Angiotensin-converting enzyme 2, University of Pennsylvania Health System, Technology, ACE2, Saliva, School, Dental plaque, Safety, Veterinary medicine, Molecular Therapy, Viral load, Multimedia, COVID, Severe acute respiratory syndrome coronavirus 2, Vaccine, Pharmaceutical industry

PHILADELPHIA, April 12, 2022 /PRNewswire/ -- A chewing gum made with a plant-grown protein "traps" the SARS-CoV-2 virus, reducing viral load in saliva and potentially tamping down transmission, according to a study led by Henry Daniell at Penn Dental Medicine .

Key Points: 
  • PHILADELPHIA, April 12, 2022 /PRNewswire/ -- A chewing gum made with a plant-grown protein "traps" the SARS-CoV-2 virus, reducing viral load in saliva and potentially tamping down transmission, according to a study led by Henry Daniell at Penn Dental Medicine .
  • This gum offers an opportunity to neutralize the virus in the saliva, giving us a simple way to possibly cut down on a source of transmission."
  • Meanwhile, another line of work by Daniell involved research to develop a chewing gum infused with plant-grown enzymes to disrupt dental plaque .
  • To find out, he contacted Ronald Collman at Penn Medicine, whose team had been collecting biospecimens from COVID patients forresearch.

World’s-First Tonsil Epithelial Organoids Model for SARS-CoV-2 Infection Published in Biomaterials

Retrieved on: 
Monday, April 4, 2022
Research, Infectious Diseases, Chemicals, Plastics, Manufacturing, Biotechnology, University, Pharmaceutical, Health, Science, Education, Chemical engineering, Korea Research Institute of Bioscience and Biotechnology, ACE2, Multimedia, Public health, Epithelium, TMPRSS2, Furin, Research, Organoid, Konkuk University, CEO, Severe acute respiratory syndrome coronavirus 2, RNA, Cha University, Tissue, Korea Research Institute of Chemical Technology, COVID-19, Immunology, Professor, Angiotensin-converting enzyme 2, Infection, Pharmaceutical industry, Vaccine

However, the generation of tonsil organoids with high reproducibility had remained a technical challenge due to the lack of their cultural system.

Key Points: 
  • However, the generation of tonsil organoids with high reproducibility had remained a technical challenge due to the lack of their cultural system.
  • View the full release here: https://www.businesswire.com/news/home/20220404005434/en/
    Worlds-first tonsil epithelial organoids model for SARS-CoV-2 infection published in Biomaterials.
  • The results of this study demonstrated that the organoids are an attractive infection model for testing tissue susceptibility or transmissibility of diverse gastrointestinal or respiratory viruses.
  • Full research Generation of human tonsil epithelial organoids as an ex vivo model for SARS-CoV-2 infection in Biomaterials:

Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury

Retrieved on: 
Tuesday, March 22, 2022
Company, Cell, Therapy, Risk, Form 10-K, Private Securities Litigation Reform Act, ACE2, Transfusion-related acute lung injury, Lung, Marketing, Growth, Annual report, ADS, HK, Patient, Proning, Hypertension, U.S. Securities and Exchange Commission, Heart, Jean-Louis Vincent, Security (finance), MD, Safety, Technology, Infant respiratory distress syndrome, Lucinactant, Inflammation, WINT, Cardiogenic shock, COVID-19, Instability, GLOBE, Respiratory distress syndrome, Extracorporeal membrane oxygenation, ECMO, FDA, Acute respiratory distress syndrome, RDS, Angiotensin-converting enzyme 2, Protein, Blood, Respiratory system, Infection, Pharmaceutical industry, Vaccine

Surfactant deficiency is known to contribute to the pathophysiology of ARDS, respiratory failure, and lung injury in patients on mechanical ventilation.

Key Points: 
  • Surfactant deficiency is known to contribute to the pathophysiology of ARDS, respiratory failure, and lung injury in patients on mechanical ventilation.
  • The Phase 2 trial was designed to assess feasibility, safety, and tolerability of administration of reconstituted lyophilized lucinactant in these critically ill patients.
  • The multicenter, single-arm study enrolled 20 critically ill patients who were intubated and on mechanical ventilation due to severe COVID-19 associated ARDS.
  • Patients received lucinactant as a liquid via the endotracheal tube assessing safety and tolerability of the administration procedure and of the drug.

BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University

Retrieved on: 
Thursday, March 17, 2022
Millipore, Concern, Technology, Myocarditis, SARS, Vaccine, World Health Organization's response to the COVID-19 pandemic, Antibody, Ohio State University, ACE2, OTCQB, Cancer, Degenerative disease, RNA transfection, Journal, Our World in Data, Observation, Clinical trial, CDMO, Company, CSE, Severe acute respiratory syndrome coronavirus 2, Deutsch, Virus, Journal of Virology, Merck, Angiotensin-converting enzyme 2, Mouse, Coronavirus, FRA, Pharmaceutical industry, Omicron, BC, Delta, COVID-19, Virology

BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University ("Ohio State") and BioVaxys, announced in December 2021, that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviruses ("pan-sarbecovirus vaccine").

Key Points: 
  • BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University ("Ohio State") and BioVaxys, announced in December 2021, that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviruses ("pan-sarbecovirus vaccine").
  • The collaboration between BioVaxys and Ohio State, which has been underway since early January 2022, is evaluating the combination of BVX-0320 and BVX-1021 in a guinea pig model.
  • For greater certainty, BioVaxys is not making any express or implied claims that the Company can currently treat COVID-19.
  • BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.

BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University

Retrieved on: 
Thursday, March 17, 2022
Millipore, Concern, Technology, Myocarditis, SARS, Vaccine, World Health Organization's response to the COVID-19 pandemic, Antibody, Ohio State University, ACE2, OTCQB, Cancer, Degenerative disease, RNA transfection, Journal, Our World in Data, Observation, Clinical trial, CDMO, Company, CSE, Severe acute respiratory syndrome coronavirus 2, Deutsch, Virus, Journal of Virology, Merck, Angiotensin-converting enzyme 2, Mouse, Coronavirus, FRA, Pharmaceutical industry, Omicron, BC, Delta, COVID-19, Virology

BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University ("Ohio State") and BioVaxys, announced in December 2021, that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviruses ("pan-sarbecovirus vaccine").

Key Points: 
  • BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University ("Ohio State") and BioVaxys, announced in December 2021, that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviruses ("pan-sarbecovirus vaccine").
  • The collaboration between BioVaxys and Ohio State, which has been underway since early January 2022, is evaluating the combination of BVX-0320 and BVX-1021 in a guinea pig model.
  • For greater certainty, BioVaxys is not making any express or implied claims that the Company can currently treat COVID-19.
  • BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.

BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein

Retrieved on: 
Wednesday, February 16, 2022
Deutsch, Millipore, Angiotensin, Tissue, Systematic review, Merck, Company, Journal, PCT, Toxic shock syndrome toxin, OTCQB, ACE2, Blood, Vaccine, RNA transfection, Hematology-Oncology and Stem Cell Transplantation Research Center, Report, Gastrointestinal tract, Platelet factor 4, DNP, COVID-19 vaccine, Liver, Myocardial infarction, FRA, Angiotensin-converting enzyme 2, CDMO, Ohio State University, RBD, Myocarditis, Mouse, CSE, Pericarditis, Severe acute respiratory syndrome coronavirus 2, COVID-19, Epithelium, Thrombosis, II, Heart, Pharmaceutical industry, BC

VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine, demonstrate that the vaccine does not bind to the Angiotensin Converting Enzyme-2 (ACE2) receptor. The finding suggests that the Company's haptenized SARS-CoV-2 spike protein vaccine may not lead to the unusual but serious myocarditis observed with mRNA vaccines. Previous studies in mice have shown that BVX-0320 stimulates a robust antibody and T cell response and was safe and well tolerated.

Key Points: 
  • Previous studies in mice have shown that BVX-0320 stimulates a robust antibody and T cell response and was safe and well tolerated.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • The Biovaxys vaccine for Covid-19, BVX-0320, comprises a portion of the SARS-CoV-2 spike protein that is modified by the hapten, dinitrophenyl (DNP); hapten modification prevents ACE2 binding while retaining immunogenicity.
  • For greater certainty, BioVaxys is not making any express or implied claims that the Company can currently treat COVID-19.

BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein

Retrieved on: 
Wednesday, February 16, 2022
Deutsch, Millipore, Angiotensin, Tissue, Systematic review, Merck, Company, Journal, PCT, Toxic shock syndrome toxin, OTCQB, ACE2, Blood, Vaccine, RNA transfection, Hematology-Oncology and Stem Cell Transplantation Research Center, Report, Gastrointestinal tract, Platelet factor 4, DNP, COVID-19 vaccine, Liver, Myocardial infarction, FRA, Angiotensin-converting enzyme 2, CDMO, Ohio State University, RBD, Myocarditis, Mouse, CSE, Pericarditis, Severe acute respiratory syndrome coronavirus 2, COVID-19, Epithelium, Thrombosis, II, Heart, Pharmaceutical industry, BC

VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine, demonstrate that the vaccine does not bind to the Angiotensin Converting Enzyme-2 (ACE2) receptor. The finding suggests that the Company's haptenized SARS-CoV-2 spike protein vaccine may not lead to the unusual but serious myocarditis observed with mRNA vaccines. Previous studies in mice have shown that BVX-0320 stimulates a robust antibody and T cell response and was safe and well tolerated.

Key Points: 
  • Previous studies in mice have shown that BVX-0320 stimulates a robust antibody and T cell response and was safe and well tolerated.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • The Biovaxys vaccine for Covid-19, BVX-0320, comprises a portion of the SARS-CoV-2 spike protein that is modified by the hapten, dinitrophenyl (DNP); hapten modification prevents ACE2 binding while retaining immunogenicity.
  • For greater certainty, BioVaxys is not making any express or implied claims that the Company can currently treat COVID-19.

NRx Announces Planned Study Investigating BriLife™ Booster Vaccine Against Omicron Variant

Retrieved on: 
Tuesday, January 11, 2022
Muscle, Research, Biology, Biotechnology, Patient, NASDAQ, Novartis, Development, JD, Israel Institute for Biological Research, US Foods, Biomedical Advanced Research and Development Authority, MPH, Vaccination, Conference, National, COVID-19, National Security Advisor (United States), IIBR-100, Company, Food, FDA, News, Dark Enlightenment, J&J, Vaccine, Hope, Fast Track, ASPE, Human services, United States Army, BARDA, Breakthrough therapy, Review, Skin, Angiotensin-converting enzyme 2, RNA transfection, ACE2, Lilly, Letter, CEO, GLOBE, Goal, Omicron, Pharmaceutical industry, Delta, Allergan, Health, Teva, Pfizer, MD

Last week, NRx met with experts from the Israel Institute for Biological Research (IIBR) to review data and research related to the ability of the BriLife vaccine to induce neutralizing antibodies against the Omicron variant.

Key Points: 
  • Last week, NRx met with experts from the Israel Institute for Biological Research (IIBR) to review data and research related to the ability of the BriLife vaccine to induce neutralizing antibodies against the Omicron variant.
  • Based on the preliminary findings, NRx is currently designing a phase 2b/3 study of the BriLife vaccine as a booster to protect against COVID-19 variants of concern including the Omicron variant.
  • In further news, the Israel Ministry of Health recently approved a study investigating the NanoPass MicronJet intradermal injection system for the BriLife vaccine.
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients.